Faculty Opinions recommendation of Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

2016 ◽  
Author(s):  
Daniele Prati ◽  
Alessandra Berzuini
Keyword(s):  
Multiple Myeloma ◽  
T Cells ◽  
Clinical Evaluation ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Engineered T Cells

scholarly journals Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Haematologica ◽  
2016 ◽  
Vol 101 (5) ◽  
pp. 616-625 ◽  
Author(s):  
E. Drent ◽  
R. W. J. Groen ◽  
W. A. Noort ◽  
M. Themeli ◽  
J. J. Lammerts van Bueren ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
T Cells ◽  
Clinical Evaluation ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Engineered T Cells

scholarly journals Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

2015 ◽  
Vol 3 (S2) ◽  
Author(s):  
Esther Drent ◽  
Richard Groen ◽  
Willy Noort ◽  
Jeroen Lammerts van Bueren ◽  
Paul Parren ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
T Cells ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor ◽  
Preclinical Evaluation ◽  
Engineered T Cells

scholarly journals Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma

2021 ◽  
Vol 10 (1) ◽  
pp. 1959102
Author(s):  
Yaru Feng ◽  
Xiuying Liu ◽  
Xiaorui Li ◽  
Yating Zhou ◽  
Zhiru Song ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
T Cells ◽  
Chimeric Antigen Receptor ◽  
Antigen Receptor

scholarly journals Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

Blood ◽  
2014 ◽  
Vol 123 (15) ◽  
pp. 2343-2354 ◽  
Author(s):  
Saar Gill ◽  
Sarah K. Tasian ◽  
Marco Ruella ◽  
Olga Shestova ◽  
Yong Li ◽  
...  
Keyword(s):  
T Cells ◽  
Acute Myeloid Leukemia ◽  
Mouse Models ◽  
Chimeric Antigen Receptor ◽  
Myeloid Leukemia ◽  
Antigen Receptor ◽  
Key Points ◽  
Human Acute Myeloid Leukemia ◽  
Engineered T Cells ◽  
Acute Myeloid

Key Points Targeting of CD123 via CAR-engineered T cells results in rejection of human AML and myeloablation in mouse models.

Sign in / Sign up

Export Citation Format

Share Document